Novartis AG
NVS
|
News
|
$95.12
0.81%
5.43%
2.3M
|
Health Technology
(0.0% 1d) (-1.0% 1m) (-5.8% 1y) (0.0% 2d) (0.0% 3d) (1.8% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 208,306,188,875
http://www.novartis.com
Sec Filling | Patents | 103914 employees
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
add to watch list Paper trade email alert is off
Press-releases
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
MOR | News | $17.96 -0.11% -0.06% 320K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
MPSYF | News | $70.28 -71.33% 110
|
Health Technology
| Email alert
Add to watchlist
sales expansion novartis growth
Over-The-Counter Drug Market size is set to grow by USD 58.54 billion from 2023-2027, Abbott Laboratories, Achelios Therapeutics Inc. and AstraZeneca Plc, and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-04-22 (Crawled : 22:00) - prnewswire.com
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.07 -0.2% -0.09% 3.8M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
| Email alert
Add to watchlist
RBGLY | News | $10.59 2.32% -2.05% 850K
|
Manufacturing
| Email alert
Add to watchlist
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.305 0.52% -14.18% 630
|
Health Technology
| Email alert
Add to watchlist
RBGPF | News | $52.06 0.6% 6.46% 4.8K
|
Consumer Non-Durables
| Email alert
Add to watchlist
drug astrazeneca set key therapeutics market
Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $548.38 0.66% 0.86% 1.2M
|
Health Technology
|
| O: -0.26%
H: 0.03%
C: -1.55%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
RGNX | $15.64 -0.32% -0.06% 440K
|
Health Technology
|
| O: -1.43%
H: 2.27%
C: -3.18%
global dna market
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | News A | $11.25 -0.13% 4.1M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | News | $20.61 3.15% 0.0% 1.6M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $15.72 0.19% 460K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | News | $900.16 0.37% 0.32% 240K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $5.075 -2.78% -2.86% 3.5M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -1.75%
H: 0.85%
C: 0.85%
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -2.52%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
BAX | $40.4 2.36% 0.0% 2.7M
|
Health Technology
|
| O: -0.1%
H: 0.13%
C: -1.08%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.32%
H: 0.96%
C: 0.22%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -2.13%
H: 0.0%
C: 0.0%
BMRN | $89.49 0.97% 0.99% 1.3M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.04%
AMGN | News | $271.91 1.11% 1.12% 1.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
set therapeutics market
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta nephropathy for novartis show
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.9 0.52% 0.54% 850K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Novartis tender offer for MorphoSys AG commences
Published: 2024-04-11 (Crawled : 09:00) - globenewswire.com
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
|
| O: -0.32%
H: 0.48%
C: -0.17%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
MOR | News | $17.96 -0.11% -0.06% 320K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -0.39%
for novartis
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Last 48 Hours Insiders Buying
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.42 1.0% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 840K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.57 0.56% 0.28% 11K
|
Consumer Non-Durables
|
20:10